Golden Throat Holdings Group Company Limited (6896.HK)
HKD 4.25
(-0.47%)
HKD 4.25
(-0.47%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 410.75 Million CNY | 2.99% |
| 2022 | 424.93 Million CNY | 61.75% |
| 2021 | 281.79 Million CNY | 47.39% |
| 2020 | 233.3 Million CNY | -23.47% |
| 2019 | 218.16 Million CNY | 31.48% |
| 2018 | 160.94 Million CNY | 108.94% |
| 2017 | 79.41 Million CNY | -52.98% |
| 2016 | 168.88 Million CNY | -11.33% |
| 2015 | 190.46 Million CNY | 16.68% |
| 2014 | 178.89 Million CNY | 79.74% |
| 2013 | 90.81 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 Q4 | 200.77 Million CNY | 17.09% |
| 2023 FY | - CNY | 2.99% |
| 2023 Q2 | 171.46 Million CNY | -44.71% |
| 2022 Q4 | 310.1 Million CNY | 252.73% |
| 2022 FY | - CNY | 61.75% |
| 2022 Q2 | 87.91 Million CNY | -40.91% |
| 2021 Q4 | 148.77 Million CNY | 52.92% |
| 2021 Q2 | 97.29 Million CNY | -33.55% |
| 2021 FY | - CNY | 47.39% |
| 2020 Q2 | 20.53 Million CNY | -86.7% |
| 2020 FY | - CNY | -23.47% |
| 2020 Q4 | 146.42 Million CNY | 613.11% |
| 2019 FY | - CNY | 31.48% |
| 2019 Q4 | 154.42 Million CNY | 142.28% |
| 2019 Q2 | 63.73 Million CNY | -49.42% |
| 2018 Q4 | 126 Million CNY | 215.61% |
| 2018 FY | - CNY | 108.94% |
| 2018 Q2 | 39.92 Million CNY | -32.27% |
| 2017 Q4 | 58.94 Million CNY | 187.89% |
| 2017 FY | - CNY | -52.98% |
| 2017 Q2 | 20.47 Million CNY | -54.95% |
| 2016 Q4 | 45.44 Million CNY | -63.19% |
| 2016 Q2 | 123.44 Million CNY | 66.38% |
| 2016 FY | - CNY | -11.33% |
| 2015 Q4 | 74.19 Million CNY | -36.19% |
| 2015 Q2 | 116.27 Million CNY | 29.52% |
| 2015 FY | - CNY | 16.68% |
| 2014 Q2 | 73.46 Million CNY | 64.11% |
| 2014 Q4 | 89.77 Million CNY | 22.19% |
| 2014 FY | - CNY | 79.74% |
| 2013 Q4 | 44.76 Million CNY | 0.0% |
| 2013 FY | - CNY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 150.4 Million HKD | -173.107% |
| Grand Pharmaceutical Group Limited | 2.96 Billion HKD | 86.154% |
| Extrawell Pharmaceutical Holdings Limited | -129.51 Million HKD | 417.135% |
| Wai Yuen Tong Medicine Holdings Limited | 113.79 Million HKD | -260.949% |
| Qianhai Health Holdings Limited | -50.22 Million HKD | 917.761% |
| Lee's Pharmaceutical Holdings Limited | 109.82 Million HKD | -274.024% |
| Essex Bio-Technology Limited | 418.37 Million HKD | 1.822% |
| Tongfang Kontafarma Holdings Limited | 76.63 Million HKD | -436.0% |
| PuraPharm Corporation Limited | -26.16 Million HKD | 1669.617% |
| SSY Group Limited | 2.11 Billion HKD | 80.575% |
| JBM (Healthcare) Limited | 204.39 Million HKD | -100.965% |
| Jacobson Pharma Corporation Limited | 429.92 Million HKD | 4.458% |
| China Resources Pharmaceutical Group Limited | 15.43 Billion HKD | 97.338% |